ORASURE TECHNOLOGIES, INC Available-for-sale Securities, Gross Unrealized Loss
ORASURE TECHNOLOGIES, INC (OSUR) reported Available-for-sale Securities, Gross Unrealized Loss of $553.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2018-02-28
- ORASURE TECHNOLOGIES, INC available-for-sale securities, gross unrealized loss for the quarter ending 2017-12-31 was $253.00K.
- ORASURE TECHNOLOGIES, INC available-for-sale securities, gross unrealized loss for the quarter ending 2017-09-30 was $245.00K.
- ORASURE TECHNOLOGIES, INC available-for-sale securities, gross unrealized loss for fiscal 2017 was $553.00K.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 6 month | Available-for-sale Securities, Gross Unrealized Loss 9 month | Available-for-sale Securities, Gross Unrealized Loss 12 month |
|---|---|---|---|---|
| 2017-12-31 | $253.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $498.00K derived: sum of 2 quarters · filed 2018-02-28 | $553.00K 10-K · filed 2018-02-28 | |
| 2017-09-30 | $245.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $300.00K 10-Q · filed 2017-11-09 | ||
| 2017-06-30 | $55.00K 10-Q · filed 2017-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |